Replies to post #195907 on Biotech Values

[DewDiligence]

ABT—Where's the benefit at this point in your observation?

Since ABSORB is statistically no worse than Xience on efficacy (what the phase-3 trials showed), ABSORB’s lack of any residual hardware in the vessel ought to be a strong selling point. For starters, ABSORB patients don’t need to take an antiplatelet drug such as Plavix for many years to eliminate the risk of late thrombosis.